GlassScriptPhysician profile
Jeffrey Ryan-Stout
NPI 1568910602
$10,681.72
in general payments reported to CMS, 2019-2025
26 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $1,337 · 2023: $2,947 · 2024: $3,610 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,439 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,438.84 |
| Education | $357.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,953.44 | 2021-2025 | |
| Amgen INC. | $2,548.42 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,608.19 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $814.85 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $603.09 | 2023-2025 | |
| Ucb, INC. | $404.33 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $344.75 | 2022-2025 | |
| Lilly USA, LLC | $298.27 | 2023-2024 | Taltz |
| Fresenius Kabi USA, LLC | $289.89 | 2023-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.40 | 2023-2024 | Cyltezo, Ofev |
| Sobi, INC | $121.19 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $79.70 | 2023-2024 | Strensiq, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $76.83 | 2023-2025 | Orencia |
| Organon LLC | $75.29 | 2024-2025 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals International, Plc | $67.69 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $39.05 | 2022 | |
| Sandoz INC. | $33.21 | 2024 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $30.33 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $25.06 | 2025 | Uptravi |
| Ani Pharmaceuticals, INC. | $22.29 | 2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals, LTD. | $21.40 | 2023 | Arcalyst |
| Radius Health, INC. | $20.38 | 2024 | Tymlos |
| Alvogen INC | $18.06 | 2023 | Teriparatide |
| Glaxosmithkline, LLC. | $16.06 | 2023 | Nucala |
| Genentech USA, INC. | $14.38 | 2024 | Actemra |
| Depuy Synthes Sales INC. | $14.17 | 2024 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ryan-Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.